{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:15:32Z","timestamp":1782177332653,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T00:00:00Z","timestamp":1683417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bmc.2023.117325","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T17:31:47Z","timestamp":1683653507000},"page":"117325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Azulene as a biphenyl mimetic in orexin\/hypocretin receptor agonists"],"prefix":"10.1016","volume":"88-89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-7971","authenticated-orcid":false,"given":"Teppo O.","family":"Leino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-7221","authenticated-orcid":false,"given":"Ainoleena","family":"Turku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-3529","authenticated-orcid":false,"given":"Lauri","family":"Urvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouni","family":"Oksanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Steynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Yli-Kauhaluoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-1564","authenticated-orcid":false,"given":"Jyrki P.","family":"Kukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.A.","family":"Wall\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117325_b0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors That Regulate Feeding Behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2023.117325_b0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The Hypocretins: Hypothalamus-Specific Peptides with Neuroexcitatory Activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2023.117325_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1152\/ajpcell.00227.2012","article-title":"Physiology of the Orexinergic\/Hypocretinergic System: A Revisit in 2012","volume":"301","author":"Kukkonen","year":"2013","journal-title":"Am. J. Physiol. - Cell Physiol."},{"key":"10.1016\/j.bmc.2023.117325_b0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The Role of Orexin in Motivated Behaviours","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bmc.2023.117325_b0025","doi-asserted-by":"crossref","unstructured":"Li, S.-B.; Giardino, W. J.; de Lecea, L. Hypocretins and Arousal. In Behavioral Neuroscience of Orexin\/Hypocretin; Lawrence, A. J., de Lecea, L., Eds.; Springer International Publishing: Cham, 2017; pp 93\u2013104. https:\/\/doi.org\/10.1007\/7854_2016_58.","DOI":"10.1007\/7854_2016_58"},{"key":"10.1016\/j.bmc.2023.117325_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/7854_2016_45","article-title":"Orexin\/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain","volume":"33","author":"Sch\u00f6ne","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.bmc.2023.117325_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/7854_2016_57","article-title":"A Decade of Orexin\/Hypocretin and Addiction: Where Are We Now?","volume":"33","author":"James","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.bmc.2023.117325_b0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.5b00832","article-title":"Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia","volume":"59","author":"Roecker","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0045","doi-asserted-by":"crossref","unstructured":"Sun, Y.; Tisdale, R. K.; Kilduff, T. S. Hypocretin\/Orexin Receptor Pharmacology and Sleep Phases. In Frontiers of Neurology and Neuroscience; 2021; pp 22\u201337. https:\/\/doi.org\/10.1159\/000514963.","DOI":"10.1159\/000514963"},{"key":"10.1016\/j.bmc.2023.117325_b0050","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide Orexin Type-2 Receptor Agonist Ameliorates Narcolepsy-Cataplexy Symptoms in Mouse Models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bmc.2023.117325_b0055","doi-asserted-by":"crossref","first-page":"45875","DOI":"10.1074\/jbc.M404136200","article-title":"Orexins Acting at Native OX1 Receptor in Colon Cancer and Neuroblastoma Cells or at Recombinant OX1 Receptor Suppress Cell Growth by Inducing Apoptosis","volume":"279","author":"Rouet-Benzineb","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0060","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1074\/jbc.M508603200","article-title":"G-Protein-Coupled OX1 Orexin\/Hcrtr-1 Hypocretin Receptors Induce Caspase-Dependent and -Independent Cell Death through P38 Mitogen-\/Stress-Activated Protein Kinase","volume":"281","author":"Ammoun","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0065","doi-asserted-by":"crossref","unstructured":"Voisin, T.; Firar, A. El; Rouyer-Fessard, C.; Gratio, V.; Laburthe, M. A Hallmark of Immunoreceptor, the Tyrosine-Based Inhibitory Motif ITIM, Is Present in the G Protein-Coupled Receptor OX1R for Orexins and Drives Apoptosis: A Novel Mechanism. FASEB J. 2008, 22 (6), 1993\u20132002. https:\/\/doi.org\/10.1096\/fj.07-098723.","DOI":"10.1096\/fj.07-098723"},{"key":"10.1016\/j.bmc.2023.117325_b0070","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1096\/fj.09-131367","article-title":"Discovery of a Functional Immunoreceptor Tyrosine- Based Switch Motif in a 7-Transmembrane-Spanning Receptor: Role in the Orexin Receptor OX1R-Driven Apoptosis","volume":"23","author":"El Firar","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.bmc.2023.117325_b0075","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-10-3473","article-title":"Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: An Openable Gate to Apoptosis","volume":"71","author":"Voisin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bmc.2023.117325_b0080","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172794","article-title":"TAK-925, an Orexin 2 Receptor-Selective Agonist, Shows Robust Wake-Promoting Effects in Mice","volume":"187","author":"Yukitake","year":"2019","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.bmc.2023.117325_b0090","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1021\/acsmedchemlett.0c00501","article-title":"Novel 5-Alkyl Pyrrolidine Orexin Receptor Agonists for Treating Sleep Disorders","volume":"11","author":"Sabnis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2023.117325_b0095","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","article-title":"Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128530","article-title":"Design and Synthesis of Novel Orexin 2 Receptor Agonists Based on Naphthalene Skeleton","volume":"59","author":"Hino","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2023.117325_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128555","article-title":"Discovery of Orexin 2 Receptor Selective and Dual Orexin Receptor Agonists Based on the Tetralin Structure: Switching of Receptor Selectivity by Chirality on the Tetralin Ring","volume":"60","author":"Iio","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2023.117325_b0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2018.09.003","article-title":"Pharmacological Characterization of the Orexin\/Hypocretin Receptor Agonist Nag 26","volume":"837","author":"Rinne","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bmc.2023.117325_b0115","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01773","article-title":"Design and Synthesis of Orexin 1 Receptor-Selective Agonists","author":"Iio","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0120","doi-asserted-by":"crossref","unstructured":"Leino, T. O.; Sieger, P.; Yli-Kauhaluoma, J.; Wall\u00e9n, E. A. A.; Kley, J. T. The Azulene Scaffold from a Medicinal Chemist\u2019s Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery. Eur. J. Med. Chem. 2022. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114374.","DOI":"10.1016\/j.ejmech.2022.114374"},{"key":"10.1016\/j.bmc.2023.117325_b0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejmech.2018.07.040","article-title":"Azulene-Based Compounds for Targeting Orexin Receptors","volume":"108","author":"Leino","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0130","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cmdc.201900074","article-title":"Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors","volume":"14","author":"Turku","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2023.117325_b0135","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1021\/acs.joc.5b02271","article-title":"Synthesis of 1,3,6-Trisubstituted Azulenes","volume":"80","author":"Leino","year":"2015","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0140","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41467-021-21087-6","article-title":"Structures of Active-State Orexin Receptor 2 Rationalize Peptide and Small-Molecule Agonist Recognition and Receptor Activation","volume":"12","author":"Hong","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bmc.2023.117325_b0145","first-page":"36","article-title":"Aligning Topology Maps While Minding the Gaps","author":"Isberg","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bmc.2023.117325_b0150","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci."},{"key":"10.1016\/j.bmc.2023.117325_b0155","doi-asserted-by":"crossref","first-page":"30806","DOI":"10.1074\/jbc.M002603200","article-title":"The Orexin OX1 Receptor Activates a Novel Ca2+ Influx Pathway Necessary for Coupling to Phospholipase C","volume":"275","author":"Lund","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2011.02.055","article-title":"Agonist Ligand Discrimination by the Two Orexin Receptors Depends on the Expression System","volume":"494","author":"Putula","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bmc.2023.117325_b0165","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1476-5381.2011.01565.x","article-title":"OX1 Orexin\/Hypocretin Receptor Activation of Phospholipase D","volume":"165","author":"J\u00e4ntti","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bmc.2023.117325_b0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(02)03101-0","article-title":"Orexin Signaling in Recombinant Neuron-like Cells","volume":"526","author":"Holmqvist","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bmc.2023.117325_b0175","doi-asserted-by":"crossref","unstructured":"Turku, A.; Rinne, M. K.; Boije af Genn\u00e4s, G.; Xhaard, H.; Lindholm, D.; Kukkonen, J. P. Orexin Receptor Agonist Yan 7874 Is a Weak Agonist of Orexin\/Hypocretin Receptors and Shows Orexin Receptor-Independent Cytotoxicity. PLoS One 2017, 12 (6), e0178526.","DOI":"10.1371\/journal.pone.0178526"},{"key":"10.1016\/j.bmc.2023.117325_b0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A Hierarchical Approach to All-Atom Protein Loop Prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"10.1016\/j.bmc.2023.117325_b0185","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the Role of the Crystal Environment in Determining Protein Side-Chain Conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bmc.2023.117325_b0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative Protein Modelling by Satisfaction of Spatial Restraints","volume":"234","author":"\u0160ali","year":"1993","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.bmc.2023.117325_b0195","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0200","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117325_b0205","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein\u2212Ligand Complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:22:05Z","timestamp":1760836925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623001736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"alternative-id":["S0968089623001736"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117325","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azulene as a biphenyl mimetic in orexin\/hypocretin receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117325"}}